XML 30 R18.htm IDEA: XBRL DOCUMENT
v3.25.3

Note 11 - Stock-Based Compensation | 9 Months Ended
--- | ---
Sep. 30, 2025
Notes to Financial Statements |
Shareholders' Equity and Share-Based Payments [Text Block] |
11. | Stock-Based Compensation
Stock-based compensation expense for the three and nine months ended September 30, 2025 and 2024 was allocated as follows:
|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
(in thousands) |  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
Cost of revenues |  | $ | 18 |  |  | $ | (30 | ) |  | $ | 79 |  |  | $ | 88 |
Sales and marketing expenses |  |  | 122 |  |  |  | 164 |  |  |  | 346 |  |  |  | 453 |
General and administrative expenses |  |  | 104 |  |  |  | 795 |  |  |  | 703 |  |  |  | 2,493 |
Research and development expenses |  |  | 80 |  |  |  | 124 |  |  |  | 268 |  |  |  | 345 |
Total stock-based compensation |  | $ | 324 |  |  | $ | 1,053 |  |  | $ | 1,396 |  |  | $ | 3,379 |
As of September 30, 2025, the total compensation costs related to unvested awards not yet recognized was $1.8 million and the weighted average period over which such costs are expected to be recognized is approximately 1.7 years. The Company did not capitalize any stock-based compensation. Restricted stock unit (“RSU”) activity for the nine months ended September 30, 2025 was as follows:
|  |  |  |  |  |  |  |  |  | Market- |  |  |  |  |  |  | Performance- |  |  |  |  |
|  | Time-Based |  |  |  |  |  |  | Based |  |  |  |  |  |  | Based |  |  |  |  |
|  | Restricted |  |  | Grant Date |  |  | Restricted |  |  | Grant Date |  |  | Restricted |  |  | Grant Date |
|  | Stock Units |  |  | Fair Value |  |  | Stock Units |  |  | Fair Value |  |  | Stock Units |  |  | Fair Value |
Balance at December 31, 2024 |  |  | 1,378,995 |  |  | $ | 3.51 |  |  |  | 558,958 |  |  | $ | 2.61 |  |  |  | 375,895 |  |  | $ | 4.19 |
Granted |  |  | 1,237,821 |  |  |  | 0.45 |  |  |  | 500,000 |  |  |  | 0.67 |  |  |  | - |  |  |  | - |
Vested |  |  | (536,145 | ) |  |  | 3.57 |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
Forfeited |  |  | (369,499 | ) |  |  | 3.56 |  |  |  | (192,473 | ) |  |  | 2.61 |  |  |  | (211,815 | ) |  |  | 4.19 |
Balance at September 30, 2025 |  |  | 1,711,172 |  |  | $ | 1.27 |  |  |  | 866,485 |  |  | $ | 1.49 |  |  |  | 164,080 |  |  | $ | 4.19 |
The aggregate fair value of RSUs that vested during the nine months ended September 30, 2025, and 2024 was $0.3 million and $0.5 million, respectively. Unvested shares related to market-based and performance-based vesting conditions are reflected at 100% of their target vesting amount in the table above. Actual vesting could range from zero to 150% of their target amounts. Performance-based RSU awards are contingent on the achievement of certain performance metrics. Compensation cost associated with performance-based RSUs are recognized based on the estimated number of shares that the Company ultimately expects will be earned. If the estimated number of shares to be earned is revised in the future, then stock-based compensation expense will be adjusted accordingly. The weighted average estimated fair value of the market condition restricted stock awards that were granted during the nine months ended September 30, 2025 was $0.67 per unit. The estimate of the fair value was determined using a Monte-Carlo valuation simulation, which included the following assumptions:
Volatility |  |  | 89.8 | %
Risk-free interest rate |  |  | 3.7 | %
Correlation coefficient |  |  | 36.5 | %
Dividend yield |  |  | - | %
Stock option activity for the nine months ended September 30, 2025 was as follows:
|  | Number of Options |  |  | Weighted-Average Exercise Price |  |  | Weighted-Average Remaining Contractual Term |  |  | Aggregate Intrinsic Value (in thousands) |
Outstanding and exercisable at December 31, 2024 |  |  | 827,458 |  |  | $ | 3.24 |  |  |  |  |  |  |  |  |
Cancelled/Forfeited |  |  | (660,755 | ) |  |  | 3.20 |  |  |  |  |  |  |  |  |
Outstanding and exercisable at September 30, 2025 |  |  | 166,703 |  |  | $ | 3.39 |  |  |  | 2.4 |  |  | $ | - |
There is no aggregate intrinsic value at September 30, 2025 because the Company’s closing stock price of $0.44 is below the exercise price of the outstanding options.

X
- References No definition available. + Details
Name: | us-gaap_DisclosureTextBlockAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP). + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContent Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505/tableOfContent + Details
Name: | us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration